pI: 5.655 |
Length (AA): 631 |
MW (Da): 70844 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
295 | 631 | 2h44 (A) | 539 | 859 | 24.00 | 0 | 1 | 0.84 | -1.8 |
300 | 627 | 1y2k (A) | 86 | 408 | 33.00 | 0 | 1 | 1.08 | -2.05 |
72 | 627 | 3ibj (B) | 307 | 897 | 18.00 | 0 | 1 | 0.988941 | 0.76 |
301 | 628 | 1zkl (A) | 139 | 454 | 32.00 | 0 | 1 | 0.97961 | -1.06 |
304 | 628 | 1taz (A) | 152 | 488 | 36.00 | 0 | 1 | 0.913555 | -0.7 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | metacyclic. | Fernandes MC |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | amastigotes. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_128202)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_50175 | Probable 3',5'-cyclic phosphodiesterase T04D3.3, putative |
Caenorhabditis elegans | CELE_T04D3.3 | Protein PDE-1, isoform B |
Cryptosporidium hominis | Chro.30269 | cGMP phosphodiesterase A4 |
Cryptosporidium parvum | cgd3_2320 | cGMP phosphodiesterase A4 |
Drosophila melanogaster | Dmel_CG44007 | CG44007 gene product from transcript CG44007-RG |
Echinococcus granulosus | EgrG_000363800 | calcium:calmodulin dependent 3'5' cyclic |
Echinococcus granulosus | EgrG_000955900 | calcium:calmodulin dependent 3'5' cyclic |
Echinococcus multilocularis | EmuJ_000363800 | calcium:calmodulin dependent 3',5' cyclic |
Echinococcus multilocularis | EmuJ_000955900 | calcium:calmodulin dependent 3',5' cyclic |
Homo sapiens | ENSG00000154678 | phosphodiesterase 1C, calmodulin-dependent 70kDa |
Homo sapiens | ENSG00000115252 | phosphodiesterase 1A, calmodulin-dependent |
Homo sapiens | ENSG00000123360 | phosphodiesterase 1B, calmodulin-dependent |
Leishmania braziliensis | LbrM.18.1190 | cAMP phosphodiesterase A, putative;with=GeneDB:LinJ18_V3.1100 |
Leishmania donovani | LdBPK_181100.1 | phosphodiesterase, putative |
Leishmania infantum | LinJ.18.1100 | cAMP phosphodiesterase A |
Leishmania major | LmjF.18.1090 | cAMP phosphodiesterase A, putative;with=GeneDB:LinJ18_V3.1100 |
Leishmania mexicana | LmxM.18.1090 | phosphodiesterase, putative |
Loa Loa (eye worm) | LOAG_08194 | PDE1B protein |
Mus musculus | ENSMUSG00000022489 | phosphodiesterase 1B, Ca2+-calmodulin dependent |
Mus musculus | ENSMUSG00000059173 | phosphodiesterase 1A, calmodulin-dependent |
Mus musculus | ENSMUSG00000004347 | phosphodiesterase 1C |
Neospora caninum | NCLIV_034660 | hypothetical protein |
Neospora caninum | NCLIV_000970 | hypothetical protein |
Neospora caninum | NCLIV_019740 | 3,5-cyclic phosphodiesterase, putative |
Plasmodium vivax | PVX_122885 | 3',5'-cyclic nucleotide phosphodiesterase, putative |
Schistosoma japonicum | Sjp_0109700 | hypothetical protein |
Schistosoma mansoni | Smp_134500 | calcium/calmodulin-dependent 35-cyclic nucleotide phosphodiesterase |
Schmidtea mediterranea | mk4.012198.00 | |
Schmidtea mediterranea | mk4.009433.01 | Probable 3',5'-cyclic phosphodiesterase pde-1 |
Schmidtea mediterranea | mk4.002472.05 | |
Schmidtea mediterranea | mk4.020233.00 | Probable 3',5'-cyclic phosphodiesterase pde-1 |
Schmidtea mediterranea | mk4.005486.00 | |
Schmidtea mediterranea | mk4.004300.00 | Probable 3',5'-cyclic phosphodiesterase pde-1 |
Schmidtea mediterranea | mk4.001910.00 | Probable 3',5'-cyclic phosphodiesterase pde-1 |
Schmidtea mediterranea | mk4.004540.01 | Probable 3',5'-cyclic phosphodiesterase pde-1 |
Schmidtea mediterranea | mk4.009433.00 | Probable 3',5'-cyclic phosphodiesterase pde-1 |
Schmidtea mediterranea | mk4.005486.01 | |
Schmidtea mediterranea | mk4.009094.00 | Probable 3',5'-cyclic phosphodiesterase pde-1 |
Trypanosoma brucei gambiense | Tbg972.10.15680 | 3, 5-cyclic nucleotide phosphodiesterase, putative |
Trypanosoma brucei | Tb927.10.13000 | cAMP phosphodiesterase A, putative |
Trypanosoma congolense | TcIL3000_10_11100 | 3', 5'-cyclic nucleotide phosphodiesterase, putative |
Trypanosoma cruzi | TcCLB.511269.40 | cAMP phosphodiesterase A, putative |
Trypanosoma cruzi | TcCLB.509805.20 | cAMP phosphodiesterase A, putative |
Toxoplasma gondii | TGME49_280410 | 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein |
Toxoplasma gondii | TGME49_272650 | 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.13000 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.13000 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.13000 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.10.13000 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_272650 | Toxoplasma gondii | Essentiality uncertain | sidik |
TGME49_280410 | Toxoplasma gondii | Essentiality uncertain | sidik |
TGME49_272650 | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_280410 | Toxoplasma gondii | Probably non-essential | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania mexicana | No drug identifiers listed for this gene. | |
Annotator: | crowther@u.washington.edu. | Comment: | Drug: 475091-30-6; Drug: 475091-31-7; Drug: 475091-32-8; Drug: 475091-33-9; Drug: 475091-34-0; Drug: 475091-35-1; Drug: 475091-36-2; Drug: 475091-37-3; Drug: 475091-38-4; Drug: 475091-39-5; Drug: 475091-40-8; Drug: 475091-41-9; Drug: 475091-42-0; Drug: 475091-44-2; Drug: 475091-45-3; Drug: 475091-46-4; Drug: 475091-47-5; Drug: 475091-48-6; Drug: 475091-49-7; Drug: 475091-51-1; Drug: 475091-52-2. chemical inhibition with newly synthesized chemicals reduced PDE activity. | References: | 11902661 | |
host cell surface binding (GO:0046812) | decreased (PATO:0000468) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 13663 20366 27775 28072 62726 160641 205908 544760 549785 549786 549788 564507 566369 566370 |
Annotator: | crowther@u.washington.edu. | Comment: | raising intracellular [cAMP] with various bioamines (which should be similar to the consequences of inhibiting PDE) prevented promastigotes from attaching to hamster macrophages. | References: | 1313882 7472855 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania tropica | 16175 |
Annotator: | crowther@u.washington.edu. | Comment: | chemical inhibition with cAMP-raising agents leads to growth inhibition . | References: | 217133 | |
cell differentiation (GO:0030154) | disrupted (PATO:0001507) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 16175 20979 158491 544760 549785 549786 549788 |
Annotator: | crowther@u.washington.edu. | Comment: | chemical inhibition with cAMP-raising agents leads to disrupted differentiation from promastigote to amastigote in cell assay. | References: | 217133 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania mexicana | 4870 8665 13663 16175 38783 183743 184309 433571 581783 581905 | |
Annotator: | crowther@u.washington.edu. | Comment: | Drug: 84166-13-2 (Cibacron blue). chemical inhibition reduced PDE activity. | References: | 10699257 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.7
Compound | Source | Reference |
---|---|---|
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References |
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | phosphodiesterase 1C, calmodulin-dependent 70kDa | Compounds | References |
Rattus norvegicus | Phosphodiesterase 1 | Compounds | References |
Bos taurus | Phosphodiesterase 1A | Compounds | References |
Homo sapiens | phosphodiesterase 1A, calmodulin-dependent | Compounds | References |
Homo sapiens | phosphodiesterase 1B, calmodulin-dependent | Compounds | References |
Target | Type | Source | Notes |
---|---|---|---|
LmjF.18.1090 | cloned gene | BRENDA | A gene with this EC number or name or sequence has been cloned from Leishmania major ( 1 ) |
2 literature references were collected for this gene.